ROCHE's HIVID APPROVED FOR MONOTHERAPY IN HIV-INFECTED PATIENTS; NEW INDICATIONS FOR COMBINATION THERAPY WITH RETROVIR COME UNDER ACCELERATED APPROVAL

Roche's Hivid is approved for second-line monotherapy in HIV- infected patients who experience disease progression with zidovudine treatment or who are intolerant to zidovudine. The new indication was approved Aug. 5.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet